Dompe Farmaceutici SpA operates as a biopharmaceutical company. It develops pharmaceutical and biotechnological drugs. The firm provides updating and scientific assistance services to doctors of general medicine, paediatrics, pneumology, otology, orthopaedics, rheumatology, physiatrist, odontology, accident and emergency and first aid stations. The company was founded by Franco Domp�� in 1940 and is headquartered in Milan, Italy.

Dompé SpA provides services of updating and scientific assistance to doctors. It offers information on therapeutic areas including physiatrics, cystic fibrosis, geriatrics, infectious diseases, internal, sleep and sports medicine, odontology, orthopedics and traumatology, otorhinolaryngology, pediatrics, pneumology, and emergency and drugs. The company was founded by Sergio Dompé in 1993 and is headquartered in L'Aquila, Italy.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

ECI, Inc. engages in the business of innovative drug discovery and its related services. It operates through the following segments: Drug Discovery Business, Drug Discovery Tool Supply and Health Food. The Drug Discovery Business segment engages in the research and development of drug discovery seeds and core technology. The Drug Discovery Tool Supply segment develops and sells laboratory equipment. The Health Food segment sells health food ingredients and agricultural supplements in bulk. The company was founded by Shiro Kanegasaki in June 1999 and is headquartered in Tachikawa, Japan.

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

CytoMed, Inc., a subsidiary of Takeda Pharmaceutical Co., Ltd., is an American company located in Cambridge, MA. The firm develops therapeutics for cancer treatment. On February 12, 1999 LeukoSite, Inc., now a subsidiary of Takeda Pharmaceutical Co., Ltd. acquired CytoMed, Inc. for $19.29 million.

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Part of The Est��e Lauder Companies, Inc., ELC Management LLC is an American company that provides management services.

HIROTSU BIO SCIENCE develops a biodiagnostic technology to help in the early detection of cancer. N-NOSE, a cancer test developed by HIROTSU BIO SCIENCE, uses urine samples and is thus non-invasive and simple, combining benefits such as high sensitivity, low costs, and early detection.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.